- Regeneron immunotherapy combo comes up short in melanoma trial<p>A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out bi…BioPharma Dive · 2mo ago↗ source
- Unlocking more value from mature drug products through strategic outsourcing<p>See how strategic outsourcing can maximize value and reduce costs for mature drug portfolios.</p>BioPharma Dive · 2mo ago↗ source
- FDA hold puts Aardvark Prader-Willi drug in limbo<figure><div><img src="https://imgproxy.divecdn.com/f5a4VRDXQg-SwH2yBDKHbtLeyVHpX8cemnSbe-t-6xU/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjI3NzEwNDk4X0F5Q…